Redeye reviews its valuation of IRLAB following the missed top-line readout with pirepemat in PD-fall. We think that there are actionable learnings from the deeper data analysis that motivate further development, most notably an analysis related to plasma concentration, but make some changes to our valuation as we expect a delay and less certain path compared to our previous assumptions.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/